眼部炎症与阿达木单抗抗体生成风险相关
该回顾性病例对照研究纳入704例接受阿达木单抗治疗至少6个月的自身免疫病患者,151例(21.5%)检出抗阿达木单抗抗体(AAA)。多因素分析显示眼部炎症、女性、阿达木单抗中断及既往TNF-α抑制剂暴露为AAA形成的独立危险因素。
要点
- 眼部炎症与AAA风险升高独立相关(aOR 2.19,95%CI 1.19-4.02,P=0.011)。
- 704例中151例(21.5%)检出AAA,比例超过五分之一。
- 既往非TNF-α抑制剂生物制剂治疗与AAA风险降低相关(aOR 0.27)。
核心结论
- 自身免疫病患者的眼部炎症与阿达木单抗抗体形成风险升高相关,但需前瞻性研究确认机制关系及治疗药物监测能否改善结局。
研究设计与样本
- 回顾性病例对照研究,利用Stanford Research Repository数据库纳入2005年6月至2024年5月接受阿达木单抗治疗至少6个月并检测药物水平或AAA的患者,共704例。
主要发现
- 151例(21.5%)检出AAA,AAA阳性组女性比例高于阴性组(60.9% vs 47.0%)。
- 多因素分析中眼部炎症(aOR 2.19;95%CI 1.19-4.02;P=0.011)、女性(aOR 1.75;95%CI 1.08-2.85;P=0.024)和阿达木单抗中断(aOR 1.74;95%CI 1.03-2.94;P=0.038)为独立危险因素。
- 既往非TNF-α抑制剂生物制剂治疗为保护因素(aOR 0.27;95%CI 0.08-0.98;P=0.046),既往TNF-α抑制剂暴露仍为危险因素(aOR 2.11;95%CI 1.25-3.55;P=0.005)。
关键数值与推荐
- AAA阳性率21.5%(151/704例),多因素分析中各因素aOR及95%CI、P值见主要发现。
临床怎么用
- 对接受阿达木单抗的自身免疫病患者,合并眼部炎症时宜关注AAA形成风险,可考虑治疗药物监测。
局限性
- 为回顾性单中心数据库研究,无法确立因果关系,作者指出需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the potential impact of ocular inflammation on development of antiadalimumab antibodies (AAAs) in patients with systemic autoimmune diseases treated with adalimumab. DESIGN: Retrospective case-control study. PARTICIPANTS: Patients who were treated with adalimumab for various autoimmune conditions for at least 6 months and were tested for adalimumab levels, AAA, or both from June 2005 through May 2024. METHODS: The Stanford Research Repository database, a clinical data warehouse that aggregates electronic health records from Stanford Health Care, Stanford Children's Health, and affiliated clinics, was used to identify eligible participants. Demographic data, systemic diagnoses, ocular involvement, and prior and concurrent treatment also were collected. Subsequently, univariable and multivariable logistic regression analyses were conducted to identify factors associated with AAA development. MAIN OUTCOME MEASURES: The correlation of AAAs with ocular inflammation and the proportion of patients with positive AAA findings in the study cohort. RESULTS: Among 704 patients, 151 patients (21.5%) demonstrated AAAs. The group was predominantly female compared with the AAA-negative group (60.9% vs. 47.0%; adjusted odds ratio [aOR], 1.75; 95% confidence interval [CI], 1.07-2.85; P = 0.024). On multivariable analysis, ocular inflammation (aOR, 2.19; 95% CI, 1.19-4.02; P = 0.011), female sex (aOR, 1.75; 95% CI, 1.08-2.85; P = 0.024), and adalimumab interruption (aOR, 1.74; 95% CI, 1.03-2.94; P = 0.038) remained independent risk factors for AAA formation. Prior biologic therapy other than tumor necrosis factor (TNF)-α inhibitors was protective (aOR, 0.27; 95% CI, 0.08-0.98; P = 0.046), although prior TNF-α inhibitor exposure remained a risk factor (aOR, 2.11; 95% CI, 1.25-3.55; P = 0.005). CONCLUSION: Ocular inflammation in patients with autoimmune disorders is associated with an increased risk of AAA formation, prospective studies are needed to determine whether this reflects a mechanistic relationship and whether therapeutic drug monitoring in this subgroup improves clinical outcomes. Notably, more than one-fifth of patients receiving adalimumab in this cohort demonstrated AAAs. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Elaraby O, El-Feky D, Hung JH, et al. Ocular Inflammation as a Risk Factor for Antiadalimumab Antibodies in Patients with Autoimmune Diseases Treated with Adalimumab. Ophthalmology. 2026. PMID: 42203133. doi:10.1016/j.ophtha.2026.05.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。